...
首页> 外文期刊>Clinical therapeutics >Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication
【24h】

Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication

机译:巴西药物检测协调:改善风险沟通的机会

获取原文
获取原文并翻译 | 示例
           

摘要

Brazilian pharmacovigilance regulations involve 3 spheres: health services, Marketing Authorization Holders (MAHs), and sanitary agency. Drug tolerability began to be effectively assessed in Brazil after the founding of the National Agency of Sanitary Surveillance, which developed the Sentinel Network Project, The objective of the Sentinel Network Project is to increase the adverse drug reaction (ADR) reporting rate by health care professionals in the hospital setting. Pharmacovigilance practices became mandatory for MAHs, and patient tolerability issues were considered in drug policy in Brazil only as recently as 2000. However, despite recent events, the regulatory advancements in pharmacovigilance in Brazil are only equivalent to international practices (ie, those of the European Union). The pharmacovigilance system in the European Union integrates the national authorities, the European Commission, and the European Medicines Agency, which is responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use in the European Union. Furthermore, ADR patient reporting is included in the new EU pharmacovigilance regulations. Numerous possible ways are available to improve the Brazilian pharmacovigilance system, mainly through regulations of biosimilar, nanotechnology, and veterinary medicines or by training health care professionals and patients to report nonserious cases and quality deviations. It is necessary to encourage and develop strategies for decentralizing pharmacovigilance actions in the whole country, as is common practice in several EU countries. Motivating and considering ADR reports by patients and improving feedback and audit practices in health care services and MAHs are also necessary measures. With the inclusion of Brazil as a member of the International Conference of Harmonization, significant changes in pharmacovigilance regulation are expected; these updates, which will consider international standards, will improve signal detection and risk communication. (C) 2019 Elsevier Inc. All rights reserved.
机译:巴西药剂法规涉及3个领域:保健服务,营销授权持有人(MAH)和卫生机构。在制定Sentinel网络项目的国家卫生监测机构的成立后,在巴西开始有效评估毒品可耐受性,该项目的目标是通过医疗专业人员增加不良药物反应(ADR)报告率在医院设置。药物事实措施是MAHS强制性的,患者耐受性问题仅在巴西的毒品政策中估计,只有2000年。然而,尽管最近的事件,巴西药所的监管进步仅相当于国际惯例(即欧洲人)联盟)。欧洲联盟的药物理解制度纳入了国家当局,欧洲委员会和欧洲药物局,该机构负责欧盟人类和兽医用药的科学评估,监督和安全监测。此外,ADR患者报告包括在新的欧盟药物检疫法规中。众多可能的方式可以改善巴西药物检测系统,主要是通过生物仿制率,纳米技术和兽医的规定或通过培训医疗保健专业人员和患者报告非法案件和质量偏差。有必要鼓励和制定欧盟国家的常见做法,鼓励和制定分散的药物检契行动。患者的激励和考虑ADR报告以及改善医疗服务和MAH的反馈和审计实践也是必要的措施。随着巴西作为国际协调会议的成员,预计药物事故监管的重大变化;这些更新将考虑国际标准,将改善信号检测和风险通信。 (c)2019 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号